Balchem Q4 Revenue Up 9.8% to $263.6M, Record EBITDA of $67.9M
Balchem delivered Q4 adjusted EPS of $1.31, surpassing the $1.18 estimate, with revenue up 9.8% to $263.6 million and record adjusted EBITDA of $67.9 million. For full year 2025, net sales hit $1.04 billion, adjusted EPS rose to $5.15, and free cash flow reached $173.6 million.
1. Strong Fourth-Quarter Results
Balchem reported adjusted EPS of $1.31 for Q4, beating the $1.18 consensus, while revenue increased 9.8% year-over-year to $263.6 million. GAAP net earnings rose 16.8% to $39.2 million and adjusted EBITDA climbed 8.1% to a record $67.9 million, supported by $67.3 million in operating cash flow.
2. Record Full-Year 2025 Performance
For the full year 2025, Balchem achieved record net sales of $1.04 billion, up 8.8%, and record adjusted EBITDA of $274.9 million. Adjusted EPS reached $5.15 compared with $4.37 in 2024, while free cash flow hit a record $173.6 million, enabling a double-digit dividend increase and continued share repurchases.
3. Financial Position and Outlook
Balchem ended 2025 with $74.6 million in cash and a net leverage ratio of 0.3x, bolstering its balance sheet for above-market growth. Management highlighted momentum across its three segments and positioned the company for continued expansion in 2026.